Analyst Price Target is $5.00
▲ +3,191.64% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Viracta Therapeutics in the last 3 months. The average price target is $5.00, with a high forecast of $11.00 and a low forecast of $2.00. The average price target represents a 3,191.64% upside from the last price of $0.15.
Current Consensus is
Moderate Buy
The current consensus among 4 contributing investment analysts is to moderate buy stock in Viracta Therapeutics. This rating has held steady since July 2024, when it changed from a Buy consensus rating.
Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California.
Read More
